EGFR and astrocytoma (excluding glioblastoma): EGFR Amp manifested as an unfavorable molecular marker for median overall survival (mOS) in all diffuse gliomas [24.2 months vs. 83.6 months, hazard ratio (HR) = 2.76, p < 0.001] and IDH-wildtype diffuse glioma (18.4 months vs. 75.3 months, HR = 2.94, p < 0.001), while not for IDH-mutant diffuse glioma (75.9 months vs. 83.6 months, HR = 1.14, p = 0.781) and astrocytoma (66.2 months vs. 59.7 months, HR = 1.28, p = 0.624).